We hope that you’ve taken the opportunity to respond to our specimen integrity survey, which remains open for a few more days. We now offer a second survey developed by Precision BioLogic Inc., asking about new approaches to monitoring our many new formulations of factor VIII and factor IX concentrate. This has become a consuming issue among laboratories that manage hemophilia A and B patients. Please click or tap here to respond to our FVIII/FIX monitoring survey. We are certain the outcomes of the survey will be helpful to you.
Mar 12 2019
Comments (0)
Anticoagulant Therapy
No comments here.